Liraglutide Helped Patients Still Obese After Bariatric Surgery Lose Significantly More Weight
Patients who remained obese 6 months after bariatric surgery lost more than twice as much weight with 12 weeks of liraglutide (1.8mg) compared to controls, with additional improvements in fatty liver and blood pressure.
Quick Facts
What This Study Found
Twelve weeks of liraglutide (1.8mg) in post-bariatric patients with persistent obesity produced 11.6% total weight loss versus 4.9% in controls, with an estimated treatment difference of 6.6% and improved metabolic outcomes.
Key Numbers
61 patients with BMI ≥28.0 kg/m² at 6 months postoperatively. Liraglutide 1.8 mg used.
How They Did This
Retrospective cohort study of 61 patients with BMI ≥28 kg/m² at 6 months post-metabolic surgery. 27 received liraglutide 1.8mg for 12 weeks; 34 were controls. Primary endpoint: change in %TWL at 24 weeks.
Why This Research Matters
Bariatric surgery doesn't work equally for everyone, and some patients need additional help losing weight. This study provides evidence that adding liraglutide relatively early after surgery can significantly boost weight loss results, potentially preventing the long-term health consequences of persistent obesity.
The Bigger Picture
The combination of bariatric surgery and GLP-1 drugs is an emerging strategy for patients with severe obesity. As more potent GLP-1 agonists become available (semaglutide, tirzepatide), the question of when and how to add pharmacotherapy after surgery becomes increasingly relevant for clinical practice.
What This Study Doesn't Tell Us
Retrospective design limits causal conclusions. Small sample size (n=61) with unequal groups. Used the lower 1.8mg dose (the weight-management dose is 3.0mg). Short treatment period (12 weeks) with 24-week follow-up. Single-center study.
Questions This Raises
- ?Would higher doses of liraglutide (3.0mg) or semaglutide produce even greater weight loss in this population?
- ?What is the optimal timing to start GLP-1 therapy after bariatric surgery?
- ?Do the weight loss benefits persist after discontinuing liraglutide in post-surgical patients?
Trust & Context
- Key Stat:
- 11.6% vs 4.9% TWL Total weight loss in liraglutide vs control groups at 24 weeks post-treatment initiation
- Evidence Grade:
- Moderate evidence from a retrospective cohort study with a meaningful sample size and clear outcomes, though limited by non-randomized design and small cohort.
- Study Age:
- Published in 2024. Addresses the growing clinical question of combining GLP-1 drugs with bariatric surgery.
- Original Title:
- The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(12), 2499-2513 (2024)
- Authors:
- Shen, Yuanyuan, Huang, Yuanhao, Ouyang, Yuqin(2), Xiang, Xinyue, Chu, Xuehui, Zhang, Bingqing, Han, Tao, Tang, Wenjuan, Feng, Wenhuan
- Database ID:
- RPEP-09252
Evidence Hierarchy
Frequently Asked Questions
Why would someone still be obese after bariatric surgery?
Bariatric surgery success varies based on factors like procedure type, starting weight, metabolism, eating habits, and genetics. Some patients don't lose enough weight or regain weight after surgery. Having a BMI still ≥28 at 6 months post-surgery suggests insufficient initial response.
Is it safe to take GLP-1 drugs after bariatric surgery?
In this study, no serious adverse events were reported with liraglutide after surgery. However, patients should work closely with their medical team, as GLP-1 drugs affect appetite and gut function, which are already altered by surgery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09252APA
Shen, Yuanyuan; Huang, Yuanhao; Ouyang, Yuqin; Xiang, Xinyue; Chu, Xuehui; Zhang, Bingqing; Han, Tao; Tang, Wenjuan; Feng, Wenhuan. (2024). The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(12), 2499-2513. https://doi.org/10.1007/s13300-024-01643-1
MLA
Shen, Yuanyuan, et al. "The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.." Diabetes therapy : research, 2024. https://doi.org/10.1007/s13300-024-01643-1
RethinkPeptides
RethinkPeptides Research Database. "The Efficacy and Safety of Liraglutide in Patients Remaining..." RPEP-09252. Retrieved from https://rethinkpeptides.com/research/shen-2024-the-efficacy-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.